Please feel free to forward to your colleagues and share the news of our journal | As a member of our research community, we would like to invite you to contribute your own research articles to Bladder Cancer, which offers contributing authors many benefits: • First class Editorial Board
• Rigorous peer review and speedy manuscript processing
• Rapid online publication (pre-press) on acceptance
• Articles are currently published Open Access with no article processing fee Submit your manuscript online via msTracker
View detailed Instructions to Authors
Aims and Scope We look forward to working with you. Best wishes, Editors-in-Chief Seth P. Lerner, MD
Scott Department of Urology
Baylor College of Medicine
Houston, Texas, USA
Email: blc@iospress.com Dan Theodorescu, MD, PhD
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California, USA
Email: blc@iospress.com | All content is currently freely available to all readers Review Article Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer
Soares, Adriana | Carmo, Rafael | Rodrigues, Catarina | Grilo, Inês Teles | Grande, Enrique Systematic Review Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions
Zuniga, Kyle B. | Graff, Rebecca E. | Feiger, David B. | Meng, Maxwell V. | Porten, Sima P. | Kenfield, Stacey A. Research Articles Salvage Hyperthermic Gemcitabine and Docetaxel Combination Chemotherapy After BCG Failure in Non-Muscle Invasive Bladder Cancer Patients
Rao, Mounica Y. | Kang, Paul | Tarajkowski, Jamaka C. | Mobley, Debra L. | Lamm, Donald L. Implementation of a Reduced Opioid Utilization Protocol for Radical Cystectomy
Greenberg, Daniel R. | Kee, Jessica R. | Stevenson, Kerri | Van Zyl, Elizna | Dugala, Anisia | Prado, Kris | Gill, Harcharan S. | Skinner, Eila C. | Shah, Jay B. Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
Drakaki, Alexandra | Kirby, Conor J. | van der Heijden, Michiel S. | Petrylak, Daniel P. | Powles, Thomas | Chi, Kim N. | Fléchon, Aude | Necchi, Andrea | Géczi, Lajos | et al. Statins are Associated with Reduced Overall and Cancer-Specific Mortality in Patients Undergoing Radical Cystectomy for Bladder Cancer
Wissing, Michel D. | O’Flaherty, Ana | Dragomir, Alice | Tanguay, Simon | Kassouf, Wassim | Aprikian, Armen G. Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-Guérin (BCG) for Non-muscle Invasive Bladder Cancer?
Al-Hogbani, Mofarej | Gilbert, Sophie | Lodde, Michele | Fradet, Yves | Toren, Paul Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes
Diamantopoulos, Leonidas N. | Khaki, Ali Raza | Grivas, Petros | Gore, John L. | Schade, George R. | Hsieh, Andrew C. | Lee, John K. | Yezefski, Todd | Yu, Evan Y. | et al. Limited Stage Small Cell Bladder Cancer: Outcomes of a Contemporary Cohort
Grigg, Claud M. | Boselli, Danielle | Livasy, Chad | Symanowski, James | McHaffie, Derek R. | Riggs, Stephen | Clark, Peter E. | Beano, Hamza | Raghavan, Derek | Burgess, Earle F. Other Content Challenging Cases in Urothelial Cancer
Soloway, Mark S. Clinical Trials Corner
Agarwal, Piyush K. | Sternberg, Cora N. Intravesical Coxsackievirus A21 Therapy for Non-Muscle Invasive Bladder Cancer
Messing, Edward | Listing articles published only in 2018 & 2019 so you can read the most popular recent content Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer (Review Article in Vol.5, Iss.2, 2019)
Ibrahim, Tony | Gizzi, Marco | Bahleda, Ratislav | Loriot, Yohann Systematic Review: Targeting HER2 in Bladder Cancer (Review Article in Vol.5, Iss.1, 2019)
Koshkin, Vadim S. | O’Donnell, Peter | Yu, Evan Y. | Grivas, Petros Radiation Therapy as Definitive Local Treatment in Patients with Limited-Stage Small Cell Carcinoma of the Bladder: Does total dose matter? (Research Article in Vol.4, Iss.3, 2018)
Germino, Elizabeth | Fischer-Valuck, Benjamin W. | Rudra, Soumon | Rao, Yuan James | Contreras, Jessika | Abraham, Christopher | Michalski, Jeff | Gay, Hiram CIS of the Bladder: Significance and Implications for Therapy (Review Article in Vol.5, Iss.3, 2019)
Mirabal, Jorge Rivera | Taylor, John A. | Lerner, Seth P. Investigating the STING Pathway to Explain Mechanisms for BCG Failures in Non-Muscle Invasive Bladder Cancer: Prognostic and Therapeutic Implications (Research Article in Vol.5, Iss.3, 2019)
Koti, Madhuri | Chenard, Stephen | Nersesian, Sarah | Vidotto, Thiago | Morales, Alvaro | Siemens, D. Robert Cisplatin Ineligibility for Patients With Metastatic Urothelial Carcinoma: A Survey of Clinical Practice Perspectives Among US Oncologists (Research Article in Vol.5, Iss.4, 2019)
Galsky, Matthew D. | Ma, Esprit | Shah-Manek, Bijal | Mills, Rosalina | Ha, Long | Krebsbach, Craig | Blouin, Eric | Tayama, Darren | Ogale, Sarika | Upcoming Webinars BCAN offers regular patient insight webinars, bringing nationally recognized bladder cancer experts directly to patients and families to address important topics related to bladder cancer diagnosis, treatment, research and quality of life. Two of the upcoming online webinars taking place include: ▪ Real Talk: Understanding Pelvic Floor Health and Therapy (Apr 21); and
▪ Understanding Cystoscopy and TURBT: What You Need To Know (May 20).
| ▪ | Real Talk: Understanding Pelvic Floor Health and Therapy (Apr 21); and | | ▪ | Understanding Cystoscopy and TURBT: What You Need To Know (May 20). | | Visit the BCAN website for more information and details about how to register for these webinars, and to access the full catalog of past webinars (videos and transcripts are available): | Help Spread the News of BLC! | If you know of any colleagues or fellow researchers who are not yet signed up to receive the newsletter, we invite you to share this mailing with them. Click on the visual or access the sign-up link here. BLC has an active social media presence. If you are not yet interacting with the journal on social media, why not take the time today to follow us on Twitter? Be part of the discussion! | You are receiving this mailing as you are signed up to receive news from BLC.
You can unsubscibe or alter your preferences at any time by clicking the links below. | |
